CORMEDIX INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- CORMEDIX INC. payments for repurchase of common stock for the quarter ending 2026-06-30 was $6.39M.
- CORMEDIX INC. payments for repurchase of common stock for the quarter ending 2026-03-31 was $11.09M.
- CORMEDIX INC. payments for repurchase of common stock for the quarter ending 2025-06-30 was $0.00.
- CORMEDIX INC. payments for repurchase of common stock for the quarter ending 2025-03-31 was $0.00.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $6.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | |
| 2026-03-31 | $11.09M 10-Q · filed 2026-05-14 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |